Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rosuvastatin + olmesartan is a fixed-dose combination drug consisting of two active pharmaceutical ingredients: rosuvastatin, an HMG-CoA reductase inhibitor (statin), and olmesartan medoxomil, an angiotensin II receptor blocker (ARB). This combination is used for the co-management of dyslipidemia (high cholesterol) and hypertension (high blood pressure), conditions that frequently coexist in patients at risk for cardiovascular disease. Rosuvastatin lowers LDL cholesterol by inhibiting HMG-CoA reductase in the liver, thereby reducing cholesterol synthesis. Olmesartan blocks the angiotensin II type 1 receptor on vascular smooth muscle, leading to vasodilation and reduced blood pressure. The fixed-dose combination aims to improve medication adherence by reducing pill burden while providing effective control of both lipid levels and blood pressure[1][2]. Clinical studies have shown that this combination is effective and safe for patients with mild to moderate hypertension accompanied by dyslipidemia[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rosuvastatin + olmesartan.